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Abstract 
Emerging data suggest that the effects of infection with SARS-CoV-2 are far reaching extending 
beyond those with severe acute disease. Specifically, the presence of persistent symptoms after 
apparent resolution from COVID-19 have frequently been reported throughout the pandemic by 
individuals labeled as “long-haulers”. The purpose of this study was to assess for symptoms at 
days 0-10 and 61+ among subjects with PCR-confirmed SARS-CoV-2 infection. The University 
of California COvid Research Data Set (UC CORDS) was used to identify 1407 records that met 
inclusion criteria. Symptoms attributable to COVID-19 were extracted from the electronic health 
record. Symptoms reported over the previous year prior to COVID-19 were excluded, using 
nonnegative matrix factorization (NMF) followed by graph lasso to assess relationships between 
symptoms. A model was developed predictive for becoming a long-hauler based on symptoms. 
27% reported persistent symptoms after 60 days. Women were more likely to become long- 
haulers, and all age groups were represented with those aged 50 ± 20 years comprising 72% of 
cases. Presenting symptoms included palpitations, chronic rhinitis, dysgeusia, chills, insomnia, 
hyperhidrosis, anxiety, sore throat, and headache among others. We identified 5 symptom 
clusters at day 61+: chest pain-cough, dyspnea-cough, anxiety-tachycardia, abdominal pain-
nausea, and low back pain-joint pain. Long-haulers represent a very significant public health 
concern, and there are no guidelines to address their diagnosis and management. Additional 
studies are urgently needed that focus on the physical, mental, and emotional impact of long-
term COVID-19 survivors who become long-haulers. 
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Introduction 
In the United States, over 28 million people have been infected with SARS-CoV-2, the virus 
responsible for COVID-19 (1), and the cumulative hospitalization rate has exceeded 1300 
persons per 100,000 since early 2020 (2).  Hospitalized patients account for 1% of COVID-19 
patients, yet most research to-date has focused on in-patients with severe disease. However, very 
little is known about the medium- and long-term consequences of COVID-19 among non-
hospitalized individuals, although emerging data suggest a significant proportion of these 
subjects experience persistent symptoms associated with antecedent SARS-CoV-2 infection. 
Those with persistent symptoms have been labeled “long-haulers” or persons with long COVID-
19. Recent estimates suggest that ~10% of hospitalized patients go on to become long-haulers (3-
5) .  However, the body of evidence regarding long- haulers, particularly among the 99% of non-
hospitalized cases, is nascent. 
Late sequelae following an infectious disease is not uncommon. However, it is unclear 
whether clinical manifestations reflect primary organ involvement during an acute infection or if 
long-term signs and symptoms are promoted by aberrant inflammatory immune response. 
Understanding the late sequelae of SARS-CoV-2 infection is limited due to small sample sizes 
and a preponderance of studies that have focused on hospitalized survivors, with very limited 
data at the population level. Further studies examining long-term outcomes in subjects with 
“milder” infection are crucial to understanding both the pathophysiology and the public health 
impact of COVID-19.  In addition, developing an understanding of host factors that predict long-
hauler status as well as potential association with symptom clusters will be pivotal to the 
development of evidence-based management guidelines. 
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In the current study, we utilized electronic health records (EHR) from community 
dwelling individuals (N=1407) with confirmed SARS-CoV-2 infection (via PCR) to determine 
symptoms and symptom clusters. Specifically, we evaluated symptoms at presentation (days 0-
10 following a COVID-19 diagnosis) and at days 61+. We defined long-haulers as persons with 
persistent symptoms at day 61+ (27%) and evaluated if early symptoms or non-modifiable 
factors (age, ethnicity) could predict likelihood of persistent symptoms at day 61+ (e.g. long-
hauler) and/or assignment within any given symptom cluster. 
Methods 
Sample Size and Inclusion Criteria 
University of California COvid Research Data Set ((UC CORDS) as of 02/04/2021) contains 
deidentified electronic records for 178971 patients treated in the state of California. Strict study 
eligibility criteria were used to obtain a sample of never-hospitalized SARS-CoV-2 infected 
individuals with COVID-19 symptoms. Patients hospitalized for COVID-19 were excluded. 
Other inclusion criteria were  individuals with at least a 5 year history within the University of 
California (UC) system, a confirmed positive RT-PCR test for SARS-CoV-2, and only 
symptoms attributable to SARS-CoV-2 were included as symptoms that were reported within the 
year prior to testing positive for SARS-CoV-2 were excluded from the analysis, records 
of  healthcare interaction following COVID-19 diagnosis, and individuals with reinfection. A 
total of 1407 participants met criteria. 
Non-Negative Matrix Factorization for Subgroup Identification 
Nonnegative matrix factorization (NMF) extracts sparse and meaningful features from 
nonnegative data from high dimensional data sets (6) and has been widely used in various 
domains including image processing, data mining and genomics to extract interpretable 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.03.21252086doi: medRxiv preprint 
components from data.  Given a binary symptom occurrence matrix Xn*s, where n is the number 
of patients, s is the number of symptoms of interest and each entry denotes the occurrence of a 
symptom for a specific patient. NMF finds two non-negative matrices (W, H) whose product 
approximates the original non-negative matrix X. W is a low-rank matrix with the rank being the 
number of components (subgroups) and the entries at each row of W matrix represent how likely 
a patient falls into each component. The columns of the H matrix illustrate the strength of 
associations between a component and symptoms, i.e. which symptoms are dominant within a 
subgroup and which symptoms are less prevalent. Here, NMF was used to extract reported 
symptoms from the EHR, and then used to identify subgroups of COVID-19 patients in order to 
identify dominant symptoms within each subgroup (symptom clusters).  
Network Analysis on Symptom Associations 
Following NMF we used graphical lasso (glasso) to determine relationships between symptoms 
at each stage (7). Glasso operates on symptom counts data and yields pairwise associations of 
symptoms which can be visualized in a network. After network structure estimation using glasso, 
walktrap algorithm was employed to cluster nodes in the network (8). 
Long-Hauler Predictor Analysis 
In order to identify factors leading to the development of persistent symptoms we developed a 
predictive model that inputs multiple potential key factors to predict if a subject with SARS-
CoV-2 infection will become a long-hauler. By inspecting the model’s coefficient strength, we 
can identify the key predictors. We formulated socio demographics, symptoms the individuals 
experienced in the first 11 days and if a patient was asymptomatic in the first 11 days as input 
features and then applied logistic regression as our predictive model. One benefit of this method 
is that we could not only identify predictors that are associated with higher risk of becoming a 
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long-hauler, but we were also able to identify predictors that may protect a subject from 
becoming a long-hauler. To alleviate the effect of multicollinearity which may cause 
misinterpretation of predictor importance, we performed hierarchical clustering on the Spearman 
rank-order correlations of input features. 
Results 
Features and Symptoms Among Community Dwelling Individuals with COVID-19: Days 0-10 
and 61+. Table 1 shows sample distribution related to age, ethnicity, and sex. Figure 1 shows 
distribution of individuals reporting symptoms at days 0-10; approximately 68% of the total 
group exhibited symptoms, with 32% being asymptomatic. Prevalent symptoms during this time 
include (in descending order) dyspnea, cough, fever, chest pain, diarrhea, anxiety, and fatigue 
(See Figure 1B). Using NMF five symptom clusters with the co-occurrence of symptoms were 
identified. Symptom network analysis was used to identify prominent symptoms (larger node 
equates to greater prominence) and the strength of their association with other symptoms, 
wherein the darker the line connecting nodes indicates a stronger relationship (See Figure 1C). 
Figure 2 depicts the non-modifiable characteristics of long-haulers reporting symptoms at 
61+ days. This group was distributed across all age-groups, including among those < 18 (34 
participants, a mean age of 9.29 years, 11/34 were ≤ age 5), ethnicities, and included more 
women than men. Symptoms that are prevalent among long-haulers include (descending order): 
chest pain, dyspnea, anxiety, abdominal pain, cough, low back pain, and fatigue (See Figure 2B). 
Using NMF five discrete clusters were identified and symptom network analysis 
identified prominent symptoms and the strength of their association with other symptoms. 
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Symptoms at Day 0-10 and Predictive Value for Presence of Persistent Symptoms and Specific 
Symptom Cluster. At days 0-10 variables including age, sex, presence of symptoms, among 
others provided insight as potential predictors for becoming a long-hauler (Figure 3). Positive 
predictors included asymptomatic presentation, heart palpitations, chronic rhinitis, among others. 
In Figure 4, we evaluated which factors at days 0-10 would most likely result in grouping within 
one the five symptom clusters identified among long-haulers. The greatest magnitude between a 
feature and membership within a cluster included initial presentation with insomnia and chest 
pain-cough cluster, anxiety and the anxiety-tachycardia cluster, and nausea with the abdominal 
pain-nausea cluster. Non-modifiable factors such as age, sex, and ethnicity did not appear to be 
associated with belonging to a specific symptom cluster. 
  
Discussion 
The current study provides much needed insight into early factors predisposing individuals for 
becoming long- haulers. These novel findings warrant additional investigations, discussion, and 
context within current knowledge about long-haulers. In reviewing our findings, we believe there 
are three key take-home points from our analyses.  
 The UC CORDS data set provides both patient-reported and clinician documented 
symptoms from SARS-CoV-2 infected patients. These symptoms are reported and recorded in 
real time which minimizes retrospective recall that has been used in the limited studies to date (4, 
9). A few other important strengths from using the UC CORDS data set is that we exclude 
symptoms reported prior to SARS-CoV-2 infection to increase confidence in symptoms being 
attributable to becoming a long-hauler. The use of the data set allowed for a broad swath of 
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symptoms, rather than being limited to a narrowly focused checklist of symptoms, which allows 
for a more sophisticated understanding of symptoms among long-haulers. 
First, our observations suggest a developing picture of long-haulers potentially reflecting 
that Caucasian race, female sex, and normal BMI as common features specific to a sub-set of 
long-haulers. Although similar descriptions have been provided in other investigations (10) and 
the lay media, further corroboration is warranted. We observed a near normal distribution of age 
among long-haulers (Figure 2A), including those under the age of 18—with the mean age at 9.29 
years. Although our study supported a potential association with female sex and higher 
likelihood of becoming a long-hauler, race appeared to be less predictive for both Caucasian and 
Hispanic ethnicity. 
There has been conflicting information regarding whether asymptomatic individuals go 
on to become long-haulers, and roughly 32% of those reporting symptoms at day 61+ in our 
study were initially asymptomatic at the time of SARS-CoV-2 testing. Age distribution of all 
SARS-CoV-2 infected individuals at day 0-11 very closely mimicked that of the long-haulers, 
suggesting the latter group  are distributed across all age groups with persons ages 50-59 range 
(± 20 years) representing more than 72% of the long-hauler population. 
Secondly, the symptom experience among those who become long-haulers changes over 
time. Data from multiple studies converge to illustrate that many hospitalized and non-
hospitalized survivors of COVID-19 experience persistent symptoms (10-16). The reported 
incidence of persistent symptoms varies; however, in the current study we report that 27% of 
community dwellers reported symptoms after 60 days. Some of the variability in symptom 
reporting and symptom association with long-haulers may be due to limitations inherent in rapid 
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screening questionnaires in as much as these questionnaires inquire about symptoms that 
predominantly impact those with severe disease. Also, questionnaires may fail to inquire about 
emerging symptoms such as cognitive dysfunction (including “brain fog”), limiting the ability to 
accurately document such symptoms. Asymptomatic individuals may be less often intensely 
monitored due to an inherent notion of low risk for severe acute disease; however, this is 
problematic as asymptomatic individuals account for 32% of the long-haulers observed in this 
study. The symptom clusters observed among long-haulers vary compared to those at initial 
presentation. The evolution of these clusters may provide insight into the etiology of long-
haulers in which elucidating sites of evolving tissue damage, and alterations in innate and 
adaptive immune inflammatory pathways might provide clarity in understanding the underlying 
pathophysiology.   
In October 2020, the Tony Blair Institute for Global Change identified key characteristics 
among long-haulers, specifically that women appear to be at greater risk and those who are of 
working age (mean of age 45) (17). Our data align with these observations. Therefore, to our 
third key point, we observed that all ethnicities were affected as well as individuals who were 
initially asymptomatic. However, our use of ethnicity is limited to broad groups and lacks needed 
specificity, a limitation imposed by how data are recorded in the EHR. We therefore also 
assessed the most recently recorded BMI among long-haulers and those who had recovered from 
COVID-19 (Supplemental Figure 1). Mean BMI among long-haulers (by age group) ranged from 
26 to 33, this may be due to limitations in our inclusion criteria (e.g. 5-year history with 
UC).  Larger population-based studies will be needed to confirm and expand upon these 
observations. Undertaking detailed immune-profiling through emerging technologies such as the 
-omics platforms may identify key host phenotypes associated with the symptom clusters that we 
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have described. We hope this article will prompt the development and implementation of 
longitudinal prospective studies that garner patient-generated reports of symptoms, rather than 
patient responses to questions generated by researchers -- this latter approach inherently 
constrained the answers we obtained. With such a new phenomenon, an ethnographic approach 
that focuses on understanding patients’ experiences would add an important lens to our analyses.  
Conclusion 
Data are emerging to suggest that infection with SARS-CoV-2 may lead to prolonged and 
persistent symptoms. These long-term consequences of becoming a long-hauler are unclear, and 
further research is urgently needed to corroborate our findings. These findings include 
identifying a cohort of long-haulers with non-modifiable risk factors, which may have predicted 
the likelihood of persistent symptoms and/or assignment within given symptom clusters. Further 
research is needed to understand the underlying pathophysiology including host phenotypes 
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Figure Legends  
Figure 1. Demographics and symptoms prevalence among SARS-CoV-2 infected 
community dwellers at days 0-10 (A) Bar and pie graphs showing distribution of age, ethnicity, 
and sex demographics (N=1345) at days 0-10. (B) Bar graph showing prevalence of symptoms 
reported at days 0-10. (C) Graph of symptom clusters with (D) corresponding bar graphs 
demonstrating symptom ranking within each cluster, and (E) symptom network analysis showing 
relationship between each reported symptom.  Each symptom is denoted as a node and the darker 
the line connecting symptoms indicates a stronger relationship. 
Figure 2. Demographics and symptom prevalence among SARS CoV-2 infected community 
dwellers at day 61+. (A) Bar and pie graphs showing distribution of age, ethnicity, and sex 
demographics (N=379) at days 61+. (B) Bar graph showing prevalence of symptoms reported at 
days 61+. (C) Graph of symptom clusters with (D) corresponding bar graphs demonstrating 
symptom ranking within each cluster, and (E) symptom network analysis showing relationship 
between each reported symptom.  Each symptom is denoted as a node and the darker the line 
connecting symptoms indicates a stronger relationship. 
Figure 3. Key features during days 0-10 and their potential as indicators for developing 
prolonged COVID-19 symptoms or being a long-hauler. Bar graph showing factors that 
positively or negatively affect the probability of developing persistent symptoms among 
COVID+ community dwellers. 
Figure 4. Presence of key indicators at days 0-10 predict inclusion into specific symptom 
clusters reported at day 61+. (A) NFM determined symptom clusters from SARS-CoV-2 
infected community dwellers at day 61+; symptom clusters are named based upon the two most 
prevalent symptoms reported within each cluster. (B) Heat map demonstrating magnitude of 
association between key predictors from day 0-10 and assignment to a cluster with darker 
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Table 1. Study Demographics 
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